Literature DB >> 14027723

A new and practical oral contraceptive agent: norethindrone with mestranol.

J H DICKINSON, G G SMITH.   

Abstract

The usefulness of a new oral contraceptive compound containing norethindrone 5 mg. and mestranol 0.075 mg. (Ortho-Novum) was studied. One hundred and seventeen private patients used this preparation for a total of 998 menstrual cycles. There were no pregnancies. Side effects were minimal and caused few (11 patients) to discontinue use. The most significant of these was weight gain and a premenstrual tension syndrome including nausea, breakthrough bleeding and skin effects. Other symptoms were minor and easily controlled. Instruction in use of the preparation is easy. Patient acceptance is excellent. Possible masculinizing effects, liver damage, or harmful effects on the uterus were checked specifically by laboratory evaluation; no significant abnormal findings were noted.This appears to be an effective oral contraceptive which is well accepted by the patient and which produced no serious side effects as used in this study.

Entities:  

Keywords:  ETHINYL ESTRADIOL; NORETHINDRONE

Mesh:

Substances:

Year:  1963        PMID: 14027723      PMCID: PMC1921561     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  5 in total

1.  Death due to liver failure following the use of methandrostenolone.

Authors:  E M WILDER
Journal:  Can Med Assoc J       Date:  1962-10-06       Impact factor: 8.262

2.  Those deceptive contraceptives.

Authors:  E J DECOSTA
Journal:  JAMA       Date:  1962-07-14       Impact factor: 56.272

3.  Cholestasis produced by the administration of norethandrolone.

Authors:  F SCHAFFNER; H POPPER; E CHESROW
Journal:  Am J Med       Date:  1959-02       Impact factor: 4.965

4.  Long-term administration of norethindrone in fertility control.

Authors:  E Rice-wray; M Schulz-contreras; I Guerrero; A Aranda-rosell
Journal:  JAMA       Date:  1962-05-05       Impact factor: 56.272

5.  Jaundice associated with norethandrolone (Nilevar) administration.

Authors:  M F DUNNING
Journal:  J Am Med Assoc       Date:  1958-07-05
  5 in total
  4 in total

1.  Blood pressure and body weight changes during oral contraceptive treatment.

Authors:  B A Chernick
Journal:  Can Med Assoc J       Date:  1968-09-28       Impact factor: 8.262

2.  An "EAR" on Environmental Surveillance and Monitoring: A Case Study on the Use of Exposure-Activity Ratios (EARs) to Prioritize Sites, Chemicals, and Bioactivities of Concern in Great Lakes Waters.

Authors:  Brett R Blackwell; Gerald T Ankley; Steven R Corsi; Laura A DeCicco; Keith A Houck; Richard S Judson; Shibin Li; Matthew T Martin; Elizabeth Murphy; Anthony L Schroeder; Edwin R Smith; Joe Swintek; Daniel L Villeneuve
Journal:  Environ Sci Technol       Date:  2017-07-18       Impact factor: 9.028

3.  Clinical evaluation of a new sequential oral contraceptive agent.

Authors:  L E Cowan
Journal:  Can Med Assoc J       Date:  1967-04-29       Impact factor: 8.262

4.  CLINICAL EVALUATION OF THE ORAL CONTRACEPTIVE USE OF NORETHINDRONE 5 MG. PLUS MESTRANOL 0.075 MG.

Authors:  J A BOARD
Journal:  Can Med Assoc J       Date:  1965-04-10       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.